Form 4: Pliant Therapeutics Executes Executive Option Repricing

Pliant Therapeutics COO Minnie Kuo participated in a board-approved stock option repricing program effective April 17, 2026.

Summary

• Pliant Therapeutics (PLRX) implemented a stock option repricing program for employees, including Chief Operating Officer Minnie Kuo.
• The repricing affected three separate option grants originally priced at $16.18, $17.44, and $11.14.
• All affected options were repriced to $1.33 per share, reflecting the closing price of the common stock on the effective date of April 17, 2026.
• The total number of options repriced for the reporting person was 245,200 shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative signal, as it reflects a necessary adjustment due to significant historical share price depreciation.

Positives

• The repricing serves as a retention mechanism for key executive talent by aligning option exercise prices with current market valuations.

Negatives

• The significant reduction in exercise price suggests a substantial decline in the company's share price since the original grant dates.
• Repricing programs can be viewed by some shareholders as dilutive or indicative of poor historical stock performance.

Risks

• Options revert to their original higher exercise prices if the executive leaves the company or is terminated for cause before the 18-month retention period expires.
• The program is subject to specific clawback conditions if a 'Sales Event' or termination occurs under certain circumstances.

Future Outlook

The company has implemented an 18-month retention period for the repriced options, during which the exercise price will revert to original levels if the executive departs or if specific conditions are not met.

Management Comments

• The repricing was approved by the board to ensure alignment of employee incentives with current market conditions.

Industry Context

StockSavvy.ai notes that option repricing is a common, albeit sensitive, practice in the biotechnology sector when share prices experience significant volatility or decline, aimed at preventing the loss of human capital.

Comparison to Industry Standards

• Repricing programs are standard in high-growth biotech firms facing depressed valuations to maintain employee retention.
• The 18-month retention period is consistent with standard corporate governance practices for executive compensation adjustments.

Corporate Governance

Stakeholder Impact

• Shareholders may experience potential dilution concerns, though the program is primarily a retention tool.
• Executives gain renewed incentive value, potentially stabilizing leadership.

Next Steps

• Monitoring of the 18-month retention period for the repriced options.
• Evaluation of future executive compensation disclosures.

Key Dates

Recommendation

The filing indicates internal efforts to retain talent following a period of stock price decline; investors should wait for further operational or clinical trial updates before adjusting positions.

Keywords

PLRX, Pliant Therapeutics, Option Repricing, Executive Compensation, Form 4, Insider Trading